argenx SE
musk agonist with broad potential in neuromuscular disease | argenx SE
Company
Deck Type
Sector
Industry
Deck date
October 2022
Slide
11 of 19
Related slides by other companies
AN2 Therapeutics
Investor Presentation
March 2025
disease potential for within projected runway | AN2 Therapeutics
AN2 Therapeutics
Investor Presentation
February 2025
disease potential for within projected runway | AN2 Therapeutics
Chimerix
Investor Presentation
May 2023
agonist | Chimerix
Chimerix
Investor Presentation
March 2023
agonist | Chimerix
Other recent decks by argenx SE
See all presentations (28 decks)
Results
February 2024
Investor Conference
January 2024
Investor Presentation
December 2023
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights